{
    "medicine_id": "c517cb363f8ba295a9ea4f4f56a449b111f4ff1c",
    "platform_id": "DB09041",
    "metadata": {
        "name": "Kerydin 43 5 mg 1mL Solution",
        "composition": "43 5 mg 1mL Tavaborole",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated for the treatment of onychomycosis a fungal infection of the toenails due to i Trichophyton rubrum i or i Trichophyton mentagrophytes i",
            "contraindications": {
                "disease": "Tavaborole is generally well tolerated with most adverse events reported as mild and not related to treatment Treatment related adverse events that occurred in 1 of participants include application site exfoliation application site erythema and application site dermatitis and ingrown toenail",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "After a single dose the mean standard deviation peak concentration Cmax of tavaborole was 3 54 2 26 ng mL n 21 with measurable concentrations range 0 618 10 2 ng mL LLOQ 0 5 ng mL and the mean AUClast was 44 4 25 5 ng hr mL n 21 After 2 weeks of daily dosing the mean Cmax was 5 17 3 47 ng mL n 24 range 1 51 12 8 ng mL and the mean AUC\u03c4 was 75 8 44 5 ng hr mL",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}